Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands.
Frequently asked questions
What sector does Acepodia, Inc. (6976) operate in?
Acepodia, Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is Acepodia, Inc. (6976) current stock price?
As of the latest data, Acepodia, Inc. stock price is NT$11.75, with a previous close of NT$11.75.
What is Acepodia, Inc. (6976) current market capitalization?
Acepodia, Inc. market cap is approximately 6.85 billion.
What is Acepodia, Inc. (6976) Earnings Per Share (EPS)?
The trailing EPS is -NT$1.36.
Does Acepodia, Inc. (6976) pay dividends?
No. Acepodia, Inc. does not pay a dividend.
What is Acepodia, Inc. (6976) beta (volatility) score?
Acepodia, Inc. has a beta of 0.511, indicating lower volatility than the overall market.